RE: Full Brazil Data16 Aug 2021 16:29
The February RNS says this about Treg induction.
"Data on pharmacokinetics of nasally administered Foralumab, immunological biomarkers, stimulation of Tregs and anti-drug antibody ("ADA") is expected to be reported in a few weeks."
The article states
" Although we hypothesize that the effect of nasal Foralumab in COVID-19 patients is related to the induction of Tregs, Treg function was not measured in the current study."
So how can they present data on something that wasn't measured.
The reduction of lung inflammation was better than the control only in the Foralumab/Dexmethasone group. So to what extent did Foralumab contribute as the lung inflammation reduction could have just been the Dexmethasone?
I really screwed up getting into this company but a useful lesson for the future, to be much more sceptical.